Literature DB >> 27252515

Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase.

Massimo Breccia1, Elisabetta Abruzzese2, Alessandra Iurlo3, Antonella Gozzini4, Alessandro Isidori5, Domenica Gangemi6, Patrizia Pregno7, Giuliana Alimena8.   

Abstract

Entities:  

Keywords:  chronic myeloid leukemia; ponatinib; prognosis

Mesh：

Substances：

Year:  2016        PMID： 27252515      PMCID： PMC5013958          DOI： 10.3324/haematol.2016.145623

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  2 in total

1.  Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor.

Authors:  David Sanford; Hagop Kantarjian; Jeffrey Skinner; Elias Jabbour; Jorge Cortes
Journal:  Haematologica       Date:  2015-09-04       Impact factor: 9.941

2.  A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

Authors:  J E Cortes; D-W Kim; J Pinilla-Ibarz; P le Coutre; R Paquette; C Chuah; F E Nicolini; J F Apperley; H J Khoury; M Talpaz; J DiPersio; D J DeAngelo; E Abruzzese; D Rea; M Baccarani; M C Müller; C Gambacorti-Passerini; S Wong; S Lustgarten; V M Rivera; T Clackson; C D Turner; F G Haluska; F Guilhot; M W Deininger; A Hochhaus; T Hughes; J M Goldman; N P Shah; H Kantarjian
Journal:  N Engl J Med       Date:  2013-11-01       Impact factor: 91.245
  2 in total
  3 in total

1.  Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option.

Authors:  Alessandra Iurlo; Daniele Cattaneo; Nicola Orofino; Cristina Bucelli; Matteo Molica; Massimo Breccia
Journal:  Clin Drug Investig       Date:  2018-05       Impact factor: 2.859

2.  Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting.

Authors:  Prajwal Boddu; Abdul Rashid Shah; Gautam Borthakur; Srdan Verstovsek; Guillermo Garcia-Manero; Naval Daver; Tapan Kadia; Farhad Ravandi; Nitin Jain; Ahmad Alhuraiji; Jan Burger; Steven Kornblau; Sherry Pierce; Sara Dellasala; Elias Jabbour; Hagop Kantarjian; Jorge Cortes
Journal:  Leuk Lymphoma       Date:  2017-10-03

3.  Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase.

Authors:  Lu Yu; Jing Liu; Xiaojun Huang; Qian Jiang
Journal:  Sci Rep       Date:  2019-11-26       Impact factor: 4.379
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.